Atilotrelvir

Atilotrelvir
Clinical data
Other names	GST-HG171
Identifiers
	IUPAC name (1S,3S,4R)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-2-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]spiro[2-azabicyclo[2.2.1]heptane-5,1'-cyclopropane]-3-carboxamide;
CAS Number	2850365-55-6;
PubChem CID	167518234;
DrugBank	DB19439;
ChemSpider	129309388;
UNII	JVV7PSN6VL;
Chemical and physical data
Formula	C24H32F3N5O4
Molar mass	511.546 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)[C@@H](C(=O)N1[C@H]2C[C@@H]([C@H]1C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)C4(C2)CC4)NC(=O)C(F)(F)F;
	InChI InChI=InChI=1S/C24H32F3N5O4/c1-22(2,3)17(31-21(36)24(25,26)27)20(35)32-14-9-15(23(10-14)5-6-23)16(32)19(34)30-13(11-28)8-12-4-7-29-18(12)33/h12-17H,4-10H2,1-3H3,(H,29,33)(H,30,34)(H,31,36)/t12-,13-,14-,15-,16-,17+/m0/s1; Key:GTRJFXDJASEGSW-KBCNZALWSA-N;

Atilotrelvir (development code GST-HG171) is a drug for the treatment of COVID-19.^[1]^[2] It has broad-spectrum anti-SARS-CoV-2 activity against different variants (including WT, β, δ, and omicron).^[3]

In combination with ritonavir, it was approved for use in China in 2023.^[4]

References

↑ Lu H, Zhang G, Mao J, Chen X, Zhan Y, Lin L, et al. (May 2024). "Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial". eClinicalMedicine. 71 102582. doi:10.1016/j.eclinm.2024.102582. PMC 11015484. PMID 38618202.
↑ Zhang G, Mao J, He H, Xu K, Zhou J, Yang Y, et al. (2023). "Discovery of GST-HG171, A Potent and Selective Oral 3CL Protease Inhibitor for the Treatment of COVID-19" (PDF). SM Journal of Infectious Diseases. 6 (9).
↑ Zhang H, Zhou J, Chen H, Mao J, Tang Y, Yan W, et al. (January 2024). "Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171". Antimicrobial Agents and Chemotherapy. 68 (1) e01115-23: e0111523. doi:10.1128/aac.01115-23. PMC 10777829. PMID 38099673.
↑ Zheng L, Wang W, Sun Q (February 2024). "Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA". Signal Transduction and Targeted Therapy. 9 (1) 46. doi:10.1038/s41392-024-01770-y. PMC 10879080. PMID 38378623.

This antiinfective drug article is a stub. You can help Wikipedia by adding missing information.

[1] Lu H, Zhang G, Mao J, Chen X, Zhan Y, Lin L, et al. (May 2024). "Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial". eClinicalMedicine. 71 102582. doi:10.1016/j.eclinm.2024.102582. PMC 11015484. PMID 38618202.

[2] Zhang G, Mao J, He H, Xu K, Zhou J, Yang Y, et al. (2023). "Discovery of GST-HG171, A Potent and Selective Oral 3CL Protease Inhibitor for the Treatment of COVID-19" (PDF). SM Journal of Infectious Diseases. 6 (9).

[3] Zhang H, Zhou J, Chen H, Mao J, Tang Y, Yan W, et al. (January 2024). "Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171". Antimicrobial Agents and Chemotherapy. 68 (1) e01115-23: e0111523. doi:10.1128/aac.01115-23. PMC 10777829. PMID 38099673.

[4] Zheng L, Wang W, Sun Q (February 2024). "Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA". Signal Transduction and Targeted Therapy. 9 (1) 46. doi:10.1038/s41392-024-01770-y. PMC 10879080. PMID 38378623.

[1]

[2]

[3]

[4]

This page was redesigned at the edge.

References